[1] Franco EL, Schlecht NF, Saslow D.The epidemiology of cervical cancer[J]. Cancer J,2003,9(5):348-359. [2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132. [3] Kurman RJ, Ellenson LH, Ronnett BM, et al.Blaustein's pathology of the female genital tract[M]// NY:Springer Science, Business Media,LLC,2011:187-233. [4] Lim S, Lee MJ, Cho I, et al.Efficacy of p16 and Ki-67 immunostaining in the detection of squamous intraepithelial lesions in a high-risk HPV group[J]. Oncol Lett,2016, 11(2):1447-1452. [5] Anais MM, Deavers EE.Biopsy interpretation of the uterine cervix and corpus[M]// Lippincott Williams &WilKins/Wolters Kluwer Heaith,2013:18-29. [6] Longatto Filho A, Utagawa ML, Shirata NK, et al.Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus[J]. Int J Gynecol Pathol,2005,24(2):118-24. [7] 吴秉铨, 刘彦仿, 周小军, 等. 免疫组织化学病理诊断[M]. 北京: 科学技术出版社,2013:467-475. [8] Darragh TM, Colgan TJ, Cox JT, et al.The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology[J]. J Low Genit Tract Dis,2012,16(3):205-542. [9] 王荣敏, 尤志学. p16蛋白表达与CINI病变进展关系的Meta分析[J]. 现代妇产科进展,2015,24(8):609-610. [10] Maniar KP, Sanchez B, Paintal A, et al.Role of the Biomarker p16 in Downgrading-IN 2 Diagnoses and Predicting Higher-grade Lesions[J]. Am J Surg Pathol,2015, 39(12):1708-1718. |